• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthValeant

Hillary Clinton Says She’s ‘Going After’ Valeant In New Campaign Ad

By
Sy Mukherjee
Sy Mukherjee
By
Sy Mukherjee
Sy Mukherjee
March 1, 2016, 12:51 PM ET
hillary clinton
Photo by Nicholas Kamm—AFP/Getty Images

Democratic presidential candidate Hillary Clinton has released a new campaign ad slamming Valeant Pharmaceuticals (VRX) for its drug price hikes and vowing to “[go] after” the embattled pharma firm.

The 30-second spot, titled “Predatory,” features a Clinton town hall from January in which she recounts an attendee’s experience with steep Valeant price increases. Clinton describes how the woman’s therapy went from a price tag of $180 for 10 shots in the 1980s to $14,700 for the same quantity today. While the ad doesn’t mention the drug’s name, Stat News reports that it is the migraine medication dihydroergotamine.

“The company is called Valeant Pharmaceuticals,” says Clinton in the ad as a picture of the drugmaker’s Bridgewater, NJ facility, complete with logo, flashes on the screen. “I’m going after them. This is predatory pricing, and we’re going to make sure it is stopped.”

The spot will reportedly be airing in Michigan and Kansas City markets.

https://www.youtube.com/watch?v=_glCj3DcPJs

Valeant has become a regular punching bag for Clinton alongside Turing Pharmaceuticals and its now-infamous former CEO, Martin Shkreli, during the 2016 election cycle. Turing and Shkreli were the subjects of previous Clinton ads slamming alleged drug company excess.

The new advertisement comes at a particularly tumultuous time for Valeant and its stock, which has dropped another 6% in Tuesday trading so far after plunging more than 18% on Monday after news broke that the firm is under a second SEC investigation. That revelation came on the same day that Valeant CEO Michael Pearson, who had been on medical leave since December with severe pneumonia, returned to his post full time.

Investors have also been fleeing Valeant over the past week after the company was forced to restate past earnings and delay a Q4 2015 earnings update. That delay was prompted by an internal audit which revealed accounting problems related to the firm’s now-defunct distributor Philidor Rx.

All told, Valeant has shed 72% of its market value in the past six months.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.